Sumitomo Pharma Dirección

Dirección controles de criterios 2/4

El CEO de Sumitomo Pharma's es Hiroshi Nomura, nombrado en Apr 2018, tiene una permanencia de 11.83 años. posee directamente un 0.018% de las acciones de la empresa, con un valor de €170.25K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 5.3 años, respectivamente.

Información clave

Hiroshi Nomura

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.1yrs
Participación del CEO	0.02%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hiroshi Nomura en comparación con los beneficios de Sumitomo Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-JP¥174b
Sep 30 2023	n/a	n/a	-JP¥135b
Jun 30 2023	n/a	n/a	-JP¥144b
Mar 31 2023	n/a	n/a	-JP¥75b
Dec 31 2022	n/a	n/a	-JP¥8b
Sep 30 2022	n/a	n/a	JP¥13b
Jun 30 2022	n/a	n/a	JP¥83b
Mar 31 2022	n/a	n/a	JP¥56b
Dec 31 2021	n/a	n/a	JP¥32b
Sep 30 2021	n/a	n/a	JP¥55b
Jun 30 2021	n/a	n/a	JP¥43b
Mar 31 2021	JP¥101m	JP¥83m	JP¥56b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Hiroshi es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Hiroshi con los resultados de la empresa.

CEO

Hiroshi Nomura (66 yo)

6.1yrs

Permanencia

JP¥101,000,000

Compensación

Mr. Hiroshi Nomura served as Director of Roivant Sciences Ltd. since September 16, 2022 until August 31, 2023. He has been Chief Executive Officer and President of Sumitomo Pharma Co., Ltd.(Formerly Sumit...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hiroshi Nomura	CEO, President & Representative Director	6.1yrs	JP¥101.00m	0.018% ¥ 168.6k
Toru Kimura	Sr. Mngg Exec. Off. of Glo. Crprate Stgy	8.3yrs	sin datos	0.013% ¥ 123.5k
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.1yrs	sin datos	0.0015% ¥ 14.2k
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.1yrs	sin datos	sin datos
Takuya Taguchi	M.E.O. of Sales & Marketing Div.	2.1yrs	sin datos	sin datos
Atsuko Higuchi	Managing Executive Officer of External Affairs	no data	sin datos	sin datos
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	3.9yrs	sin datos	0.0038% ¥ 35.7k
Koichi Kozuki	E.O. of R. Aff.	1.3yrs	sin datos	sin datos
Shigeyuki Nishinaka	Managing Executive Officer of Business Development & Management and Director	7.1yrs	sin datos	0.0020% ¥ 19.0k
Isao Shimizu	Executive Officer	1.3yrs	sin datos	sin datos
Kenji Ueno	Executive Officer	1.3yrs	sin datos	sin datos
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.1yrs	sin datos	sin datos

3.1yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DPM se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hiroshi Nomura	CEO, President & Representative Director	11.9yrs	JP¥101.00m	0.018% ¥ 168.6k
Toru Kimura	Sr. Mngg Exec. Off. of Glo. Crprate Stgy	7.9yrs	sin datos	0.013% ¥ 123.5k
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	1.9yrs	sin datos	0.0015% ¥ 14.2k
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	3.9yrs	sin datos	0.0038% ¥ 35.7k
Shigeyuki Nishinaka	Managing Executive Officer of Business Development & Management and Director	10.1yrs	sin datos	0.0020% ¥ 19.0k
Saeko Arai	Independent Outside Director	5.9yrs	sin datos	sin datos
Minoru Usui	Independent Outside Director	2.9yrs	sin datos	sin datos
Nobuhiro Endo	Independent Outside Director	4.9yrs	sin datos	sin datos
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	5.9yrs	sin datos	0.0053% ¥ 49.9k
Yoshio Iteya	Outside Audit & Supervisory Board Member	5.9yrs	sin datos	sin datos
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	less than a year	sin datos	0.0020% ¥ 19.0k
Koji Fujimoto	Independent Outside Director	1.9yrs	sin datos	sin datos

5.4yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de DPM se considera experimentada (5.3 años de antigüedad promedio).

Sumitomo Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: JP¥126 loss per share (vs JP¥28.24 loss in 3Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings released: JP¥72.68 loss per share (vs JP¥96.63 loss in 2Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

New major risk - Share price stability

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Now 22% undervalued after recent price drop

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

Now 28% undervalued after recent price drop

First quarter 2024 earnings released: JP¥97.83 loss per share (vs JP¥78.30 profit in 1Q 2023)

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Full year 2023 earnings released: JP¥188 loss per share (vs JP¥142 profit in FY 2022)

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022)

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Upcoming dividend of JP¥14.00 per share

Now 20% undervalued

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥78.30 (vs JP¥12.09 in 1Q 2022)

Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥142 (vs JP¥142 in FY 2021)

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of JP¥14.00 per share

Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational Realignment

Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022

Now 22% undervalued after recent price drop

Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS JP¥79.66 (vs JP¥47.92 in 2Q 2021)

Upcoming dividend of JP¥14.00 per share

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS JP¥12.09 (vs JP¥45.96 in 1Q 2021)

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Myovant Sciences and Pfizer Inc. Receives FDA Approval for MYFEMBREE

Sumitomo Dainippon Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥142 (vs JP¥103 in FY 2020)

Sumitomo Dainippon Pharma Co., Ltd Announces That They Will Initiate A Phase 1 Clinical Study of Dsp-0038 in the United States for the Treatment of Alzheimer’S Disease Psychosis

Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year 2022

Sumitomo Dainippon Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2021

Upcoming dividend of JP¥14.00 per share

New 90-day high: €14.90

Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers, Effective from April 1, 2021